Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.64 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.60 |
| ▸ | SMC2 | O95347 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.60 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.60 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.60 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13841957 | 0.91 | MAP2K1 (0.62) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL14499777 | 0.89 | MAP2K1 (0.52) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL3968686 | 0.84 | MAP2K1 (0.43) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL3975021 | 0.84 | MAP2K1 (0.43) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL5420237 | 0.82 | MAP2K1 (0.55) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL29669575 | 0.81 | MAP2K1 (0.66) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL28759974 | 0.81 | MAP2K1 (0.66) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL15088115 | 0.80 | MAP2K1 (0.49) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL13223755 | 0.80 | MAP2K1 (0.69) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL14499775 | 0.79 | MAP2K1 (0.49) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673339-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7511058-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511058-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511058-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7271178-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271178-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7230099-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230099-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2007022529-A2 | METHOD OF TREATING INFLAMMATORY DISEASES | ARRAY BIOPHARMA INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | MAP2K1 92/4885MAP2K2 85/4885SMC2 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.